Madeleine Williams
Stock Analyst at Canaccord Genuity
(2.96)
# 2,753
Out of 4,792 analysts
93
Total ratings
48.6%
Success rate
3.9%
Average return
Main Sectors:
Stocks Rated by Madeleine Williams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: NEU Neuren Pharmaceuticals Limited | Reiterated: Buy | $24.76 | $20.21 | +22.51% | 8 | Aug 29, 2026 | |
| ASX: CUV Clinuvel Pharmaceuticals Limited | Downgraded: Hold | $27.90 → $9.52 | $8.01 | +18.85% | 3 | Aug 27, 2026 | |
| ASX: MSB Mesoblast Limited | Reiterated: Buy | $3.56 | $2.17 | +64.06% | 7 | Aug 27, 2026 | |
| ASX: MYX Mayne Pharma Group Limited | Reiterated: Buy | $3.83 → $3.75 | $3.00 | +25.00% | 5 | Aug 27, 2026 | |
| ASX: EBR EBR Systems, Inc. | Reiterated: Buy | $2.27 → $1.91 | $0.28 | +594.55% | 12 | Aug 21, 2026 | |
| ASX: ATH Alterity Therapeutics Limited | Reiterated: Buy | $0.95 | $0.48 | +97.92% | 5 | Aug 13, 2026 | |
| ASX: CU6 Clarity Pharmaceuticals Ltd | Reiterated: Buy | $8.41 | $2.24 | +275.45% | 12 | Aug 10, 2026 | |
| ASX: M7T Mach7 Technologies Limited | Reiterated: Hold | $0.27 → $0.32 | $0.26 | +23.08% | 3 | Jul 30, 2026 | |
| ASX: BOT Botanix Pharmaceuticals Limited | Reiterated: Buy | $0.14 | $0.02 | +636.84% | 6 | Jul 29, 2026 | |
| ASX: SNT Syntara Limited | Reiterated: Buy | $0.15 | $0.02 | +525.00% | 9 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.28 | $1.81 | +25.97% | 7 | Jul 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3.15 | $3.01 | +4.65% | 5 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.84 | $2.32 | +22.41% | 3 | Jun 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180.82 → $168.62 | $166.87 | +1.05% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1.27 → $0.40 | $0.04 | +809.09% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27.33 → $27.41 | $16.76 | +63.54% | 2 | Oct 15, 2025 |
Neuren Pharmaceuticals Limited
Aug 29, 2026
Reiterated: Buy
Price Target: $24.76
Current: $20.21
Upside: +22.51%
Clinuvel Pharmaceuticals Limited
Aug 27, 2026
Downgraded: Hold
Price Target: $27.90 → $9.52
Current: $8.01
Upside: +18.85%
Mesoblast Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.56
Current: $2.17
Upside: +64.06%
Mayne Pharma Group Limited
Aug 27, 2026
Reiterated: Buy
Price Target: $3.83 → $3.75
Current: $3.00
Upside: +25.00%
EBR Systems, Inc.
Aug 21, 2026
Reiterated: Buy
Price Target: $2.27 → $1.91
Current: $0.28
Upside: +594.55%
Alterity Therapeutics Limited
Aug 13, 2026
Reiterated: Buy
Price Target: $0.95
Current: $0.48
Upside: +97.92%
Clarity Pharmaceuticals Ltd
Aug 10, 2026
Reiterated: Buy
Price Target: $8.41
Current: $2.24
Upside: +275.45%
Mach7 Technologies Limited
Jul 30, 2026
Reiterated: Hold
Price Target: $0.27 → $0.32
Current: $0.26
Upside: +23.08%
Botanix Pharmaceuticals Limited
Jul 29, 2026
Reiterated: Buy
Price Target: $0.14
Current: $0.02
Upside: +636.84%
Syntara Limited
Jul 8, 2026
Reiterated: Buy
Price Target: $0.15
Current: $0.02
Upside: +525.00%
Jul 4, 2026
Reiterated: Buy
Price Target: $2.28
Current: $1.81
Upside: +25.97%
Jun 11, 2026
Reiterated: Buy
Price Target: $3.15
Current: $3.01
Upside: +4.65%
Jun 6, 2026
Reiterated: Buy
Price Target: $2.84
Current: $2.32
Upside: +22.41%
May 12, 2026
Reiterated: Buy
Price Target: $180.82 → $168.62
Current: $166.87
Upside: +1.05%
Mar 13, 2026
Reiterated: Buy
Price Target: $1.27 → $0.40
Current: $0.04
Upside: +809.09%
Oct 15, 2025
Reiterated: Buy
Price Target: $27.33 → $27.41
Current: $16.76
Upside: +63.54%